Emrosi™ (minocycline hydrochloride extended-release capsules) is now available for the treatment of inflammatory lesions (papules and pustules) of rosacea ...

FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for RosaceaEmrosi Initial Distribution Ongoing; First ...

Journey Medical (DERM) announced the launch of and the first prescriptions filled for Emrosi(TM) (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended ...

UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinomaWALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE ...

In a recent SEC filing, a major technology company disclosed a significant reshuffle of its executive team. The changes come as the firm seeks to streamline operations and adapt to market challenges.

Exelixis, Inc announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older with ...

In a recent SEC filing, a major technology company disclosed a significant reshuffle of its executive team. The changes come as the firm seeks to streamline operations and adapt to market challenges.

Christine M. Slover, PharmD, Infectious Diseases Fellow, Keith A. Rodvold, PharmD and Larry H. Danziger, PharmD, Professor, Department of Pharmacy Practice ...